MK-2866 ((2S) -3- (4-cyanophenoxy) -N- [4-cyano-3- (trifluoromethyl) phenyl] -2-hydroxy-2-methylpropanamide, ostaryna) as a selective androgen receptor modulator has a strong, comparable to testosterone anabolic effects, while reduced androgenic effect. It enhances the processes of creating muscle tissue and improves bone mineralization.
The clinical dose (3 mg / day) - administration for 12 weeks of Ostarine leads to an increase in the total mass and muscle strength. It does not cause changes in the concentrations: free testosterone, DHT, estradiol, FSH and LH. This leads to a significant decrease in the hormone-binding globulin (SHBG), which is associated with a reduction in the amount of total testosterone. Without affecting insulin levels, lowers fasting blood glucose and decreases levels of insulin, which improves the activation of anabolic processes in the body and reduces the risk of type 2 diabetes reduces serum triglycerides, total cholesterol, HDL cholesterol and improves the LDL / HDL ratio, reducing the risk of cardiovascular disease.